TA Medical Lead, Bone Health & Rare Disease
About the job
- Doctorate degree and 3 years of directly related experience, or a bachelor's degree and 5 years of directly related experience.
- Be based in Malaysia and able to travel within the country and between Malaysia and Singapore.
- Demonstrated ability as a medical expert in a complex matrix environment.
- Knowledge of pharmaceutical product development, product lifecycle, and commercialization processes, and understanding of functions including Clinical Operations, Commercial, Safety, Regulatory, Value & Access, and Medical Affairs.
- Product and therapeutic area knowledge.
- Experience in regional or local medical practice and healthcare ecosystems.
- Skill in engagement and scientific exchange with the external medical community.
- Clinical research experience.
- In-depth understanding of the scientific method and clinical applications based on medical, scientific, and practical rationale.
- Familiarity with clinical research and clinical trial design concepts, including biostatistics.
- Sound scientific and clinical judgment.
- Knowledge of Good Clinical Practices, regional regulations and guidelines, and applicable international regulatory requirements.
- Familiarity with the local pharmaceutical industry and legal and health-system environment.
- Ability to present ideas effectively and document complex medical and clinical concepts in writing and orally.
- History of solving problems while exhibiting sound judgment and a balanced, realistic understanding of issues.
- A network of medical and clinical contacts in the product or therapeutic area.
- Support development and execution of patient-focused medical strategies that maximize the value proposition of Amgen therapies, including annual strategic planning and goal setting, launch support, and lifecycle management, in collaboration with the Medical Product Lead and/or Medical TA Head, appropriate cross-functional teams, and governance.
- Contribute to cross-functional stakeholder teams shaping the healthcare ecosystem by enabling access to medicines through evidence generation, communication, and education about medical and economic value.
- Synthesize and integrate insights to provide medical input to relevant cross-regional and functional strategies, including brand strategy.
- Foster and enhance collaboration and coordination across Medical.
- Contribute to scientific engagement strategy development across stakeholders to strengthen external understanding of unmet need and product value.
- Lead or support relationships with the external healthcare community, including scientific exchange with opinion leaders, payers, and societies where appropriate.
- Develop or support and lead or support execution of medical evidence-generation strategy to shape products and inform medical practice, aligning with global product medical and brand strategies and ensuring key needs are met.
- Foster Amgen’s reputation as a science-based, innovative, patient-focused, and reliable partner.
- Develop or contribute to advocacy plans and strategies with internal stakeholders and lead relationships as appropriate.
- Partner with or support Global Regulatory Affairs and Safety in risk-management and risk-minimization activities and communicate implications to internal and external stakeholders.
- Serve as a member and Medical representative of relevant leadership, governance, and cross-functional teams.
- May develop and manage the medical product budget.
- Recruit, retain, coach, mentor, motivate, and develop talent as appropriate.
- Ensure medical activities comply with applicable laws, regulations, and standard operating procedures.
- Ensure product-, disease-state-, and pipeline-specific medical training, and deliver training to others where appropriate.
- Ensure appropriate clinical-trial conduct as a key medical interface in close partnership with Global Development Operations, such as Site Management.
- Provide strategic input into labels, regulatory, reimbursement, policy, and promotional materials used to support internal and external interactions.
- Determine the scientific and medical subject-matter appropriateness of labels, regulatory, reimbursement, policy, promotional, and medical deliverables, such as slide decks, publications, and educational activities, through the appropriate review process.
- Contribute to strategy development for medical communications and related activities; review, approve, and ensure dissemination of product narratives, scientific platforms, core content, publications including FPR/FLR, medical education, and congresses.
- Provide support and leadership for advisory boards and other relevant meetings, such as investigator meetings and expert panels.
- Lead or support development of data interpretation, analysis, and communication for medical-executed studies.
- Make decisions on independent medical education, donations, medical grants, and sponsorships where appropriate.
- Use global infrastructure to track, measure, and evaluate performance and ensure continuous performance improvement.
- Understand key external stakeholders’ expectations to support appropriate access to Amgen therapies.
- Partner with cross-functional teams to ensure informed budget and resource trade-offs as appropriate.
- Facilitate Investigator Sponsored Studies through Amgen governance and manage the study lifecycle, including communicating with investigators as appropriate and ensuring accurate reporting of key milestone data.
- Contribute to the lifecycle management plan.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.